Skip to main content
Search form
Search
Subscribe to newsletter +
European Association of Hospital Pharmacists
Menu
Main menu
Home
About Us
Who we are
Board
Staff
Students
Transparency
Contact Information
Call for Expressions of Interest
Members
Associate membership
News
Press Releases
EAHP Newsletters
EAHP in the news
Multimedia Gallery
Events
Calendar
Academy
Synergy Masterclass
Congresses
General Assemblies
Accreditations
EAHP Synergy Certification Courses
Open Learning
Get Involved
Sponsors and partners
28th Congress of the EAHP
HP Practice
EAHP COVID-19 Resource Centre
European Statements of Hospital Pharmacy
What hospital pharmacists do
EAHP-ESCP Oath to Society
FIP global statements
National legislation on hospital pharmacy
Good Practice Initiatives
Common training framework
Environmental Sustainability
Investigation of the hospital pharmacy profession in Europe
SIGs
Controlled Substances Management
Automated Medication Management
Working Towards Eliminating Avoidable Harm
Hazardous Medicinal Products
Hospital Pharmacist’s Preparedness for in-vivo gene therapy medicinal products
Investigation of Medication Errors in Intensive Care Units
Use of Prefilled Syringes in Intensive Care Units and Operating Theaters
Policy
Resources
Consultations
Position Papers
Get involved and keep up to date
Access to Medicines
Ageing society
Infectious Diseases and AMR
ATMPs
Bar coding medicines to the single unit
Biosimilar medicines
Clinical trials
COVID-19
Digital Health
EMA - EAHP collaboration
European List of Emergency Medicines
Falsified Medicines
Hazardous Medicinal Products
Hospital Pharmacy Specialisation
Medical device regulation
Medicines shortages
Patient safety
Pharmaceuticals in the environment
Pharmacy preparations and compounding
Procurement
Public spending austerity
SmPC
Vaccination
Workforce
Statements
GPIs
Publications
2019 EP Election Manifesto
General information
EAHP Annual report
European Journals of Hospital Pharmacy
EAHP Surveys of HP practice
EAHP History Book
Practical Pharmaceutics
Congress presentation webcasts
Member Center
You are here
Home
Section 3: Production and Compounding
3PC-034
DEVELOPMENT AND VALIDATION OF A METHOD FOR THE DETERMINATION OF VANCOMYCIN EYE DROPS BY ULTRAVIOLET-VISIBLE SPECTROPHOTOMETRY
3PC-031
PHYSICOCHEMICAL STABILITY OF helen.linxweiler@unimedizin-mainz.de DILUTED ‘THIOTEPA RIEMSER’ INFUSION SOLUTIONS IN PREFILLED 5% GLUCOSE INFUSION BAGS
3PC-013
PHARMACEUTICAL COMPOUNDING IN PAEDIATRIC PATCH TESTING: ARE WE SURE ABOUT THE ACTUAL ACTIVE INGREDIENT CONCENTRATION?
3PC-006
EVALUATION OF PARENTERAL NUTRITION COMPOUNDING THROUGH A CHECKLIST
3PC-016
VANCOMYCIN EYE DROPS AT 50 MG/ML : PHYSICOCHEMICAL STABILITY, IMPACT OF PACKAGING AND STORAGE CONDITIONS
3PC-014
EVALUATION OF THE MICROBIOLOGICAL QUALITY OF NONSTERILE DRUGS PREPARED IN A HOSPITAL PHARMACY
3PC-005
SELECTION OF AN OSMOLARITY VALIDATION MODEL FOR NOMINATIVE PARENTERAL NUTRITION
3PC-022
PH STABILITY OF TETRACAINE SOLUTIONS FOR SURFACE ANAESTHESIA
3PC-004
INSULIN EYE DROP FORMULATION: EFFECTIVENESS, SAFETY AND PATIENT SATISFACTION
3PC-002
GLASS AMPOULES AND DRUG FILTRATION: ¿HOW MUCH DO WE KNOW ABOUT IT?
3PC-020
CHEMICAL STABILITY AND PHYSICAL COMPATIBILITY OF INSULIN EYE DROPS USED IN CLINICAL PRACTICE
3PC-017
Assessing the stability of Sandoz rituximab biosimilar after exposure to out-of-fridge conditions for 21 days
3PC-009
STANOZOLOL RAPID HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) QUANTIFICATION METHOD FOR QUALITY CONTROL
3PC-035
Minimising Waste In Oncology
3PC-033
Y-site Compatibility of Intravenous Nefopam with Medications Commonly Used in Intensive Care Units
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »
Follow Us